In 2014, the Joint United Nations Programme on HIV and AIDS established global targets
such that 90% of people with HIV will be diagnosed, 90% of those diagnosed will be on …

After 15 years of global scale-up of antiretroviral therapy (ART), rising prevalence of HIV
drug resistance in many low-income and middle-income countries (LMICs) poses a growing …

Background Due to the high prevalence of resistance to NNRTI-based ART since 2018,
consolidated recommendations from the WHO have indicated dolutegravir as the preferred …

Background Increased second-line antiretroviral therapy (ART) failure rate narrows future
options for HIV/AIDS treatment. It has critical implications in resource-limited settings; …

To improve virological suppression and address the emerging threat of HIV drug resistance,
many low-income and middle-income countries are moving away from non-nucleoside …

Despite extensive global efforts, sub-Saharan Africa remains disproportionately affected by
the HIV epidemic. This generalized epidemic can be seen in Lesotho which in 2014 the HIV …

Epidemiology of HIV drug resistance in low- and middle-incom... : Current Opinion in HIV and
AIDS Epidemiology of HIV drug resistance in low- and middle-income countries and WHO …

Objective: To estimate the prevalence of NRTI and NNRTI drug resistance mutations in
patients failing NNRTI-based ART in Southern Africa. Study design: We conducted a …

Objectives Real-world experience with coformulated bictegravir, emtricitabine, and tenofovir
alafenamide (BIC/FTC/TAF) is sparse as a switch regimen among people living with HIV …

Background This prospective pilot study explored same-day point-of-care viral load testing
in a setting in Ghana that has yet to implement virological monitoring of antiretroviral therapy …